Abstract:Objective To investigate the expression profiles and implication of IL-33 and its receptor ST2 in a murine model of acute liver failure (ALF)induced by D-GalN/LPS.Methods The ALF murine model was set up by intraperitoneal injection of D-GalN (900 mg/kg)/LPS(10 ug/kg),and confirmed by histopathology and biochemistry.Dynamic expression profiles of IL-33 and its receptor ST2 in ALF murine model were investigated by quantitative polymerase chain reaction (q-PCR),western-blot,enzyme-linked immune-sorbent assay (ELISA)and immunohistochemistry at different time points, respectively.Results The murine model of ALF was successfully established by intraperitoneal injection of D-GalN (900 mg/kg)/LPS(10 ug/kg).The mRNA level of intra-hepatic IL-33 continuously increased with the progression of ALF,and reached the peak at 7 h after D-GalN/LPS challenge.Compared to baseline,intra-hepatic ST2L protein level was markedly up-regulated at 3 h,which was before the occurrence of obvious hepatocytes damage.However,it declined later on and fall to the lowest at 7 h.In addition,it was observed that IL-33 protein level in serum was elevated sustainedly over time and reached the highest level at 7 h,which was consistent with its dynamic mRNA changes.In contrast,the serum level of sST2 had no significant differences between 0 h and 3 h at the early stage of liver damage,but showed an obvious rise to climax at 5 h in the medium-term of liver damage,and then was followed by a drastic decline.The immunohistochemistry results confirmed that intra-hepatic IL-33 was mainly located in the nucleus of endothelial cells and sinusoidal cells in ALF mouse liver.Conclusion The dynamic changes of IL-33 and its receptor ST2 in ALF mice are closely linked with the progression of acute liver failure,suggesting that IL-33/ST2 axis is indeed involved in the process of ALF.This might provide a novel potential target for ALF treatment.

IL-33-ST2 Axis in Liver Disease: Progression and Challenge

Role of IL-33 in Transplant Biology

Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells

Interleukin-33/serum stimulation-2 pathway: Regulatory mechanisms and emerging implications in immune and inflammatory diseases

Blockade of IL-33 ameliorates Con A-induced hepatic injury by reducing NKT cell activation and IFN-γ production in mice

IL-33:activation, regulation and function

Blockade Of Il-33 Ameliorates Con A-Induced Hepatic Injury By Reducing Nkt Cell Activation And Ifn-Gamma Production In Mice

High Expression of Interleukin-33/ST2 Predicts the Progression and Poor Prognosis in Chronic Hepatitis B Patients with Hepatic Flare

The Role of IL-35 in the Pathophysiological Processes of Liver Disease

The expression profiles and significance of IL-33 and its receptor ST2 in a murine model of D-GalN/LPS-induced acute liver failure

The IL-33-ST2-MyD88 Axis Promotes Regulatory T Cell Proliferation in the Murine Liver

Serum IL-33 Levels Are Associated with Liver Damage in Patients with Chronic Hepatitis C

IL‑33 and kidney disease (Review).

Immune Function of Interleukin-33 and Its Relation to Human Diseases

The Role of the IL-33/ST2 Axis in Autoimmune Disorders: Friend or Foe?

Advance in the research of relationship between IL-33 and the relevant diseases

Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis

Research Progress in Association Between Interleukin-23 and Liver Diseases

IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases.

Signaling and Functions of Interleukin-33 in Immune Regulation and Diseases

Dual Immune Regulatory Roles of Interleukin-33 in Pathological Conditions